PLEASANTON, Calif.—The Cooper Companies, Inc. (NYSE:COO) announced financial results for the fiscal second quarter ended April 30, 2017.

For the period, revenue increased eight percent year-over-year to $522.4 million. CooperVision (CVI) revenue rose four percent to $408.5 million while CooperSurgical (CSI) revenue climbed 23 percent to $113.9 million.

Commenting on the results, Robert S. Weiss, Cooper’s president and CEO, said, “I am pleased to report another strong quarter. CVI grew faster than the market across all geographies driven by success with its silicone hydrogel products and CSI also posted a solid quarter led by its fertility business. As we move into the second half of the fiscal year, we believe we are well positioned to continue posting strong results.”

Second Quarter GAAP operating results reflected gross margins of 66 percent compared with 62 percent in last year’s second quarter. On a non-GAAP basis, gross margin was 66 percent compared with 63 percent last year, positively impacted, the company said, primarily by favorable currency and product mix within CooperVision led by Biofinity.

Operating margin of 22 percent compared with 19 percent in last year’s second quarter. On a non-GAAP basis, operating margin was 27 percent vs. 24 percent last year.

Total debt decreased $37.6 million from January 31, 2017, to $1,386.9 million, primarily due to operational cash flow generation and subsequent debt pay down, the company said.

Cash provided by operations of $131.6 million were offset by capital expenditures of $28.5 million, resulting in free cash flow of $103.1 million.

In the Q2 period, CooperVision’s revenue included $131.8 million in sales of toric lenses, a nine percent change from the prior year period, accounting for 32 percent of CVI’s revenue. Multifocal contact lenses rose one percent to $42.9 million for the period, accounting for 10 percent of CVI revenue. Single-use spheres rose seven percent to $104.1 million for the period, accounting for 26 percent of CVI revenue while non single-use sphere ‘other’ accounted for $129.7 million, or 32 percent of CVI revenue.

In terms of geographic sales, CooperVision CVI sales in the Americas grew four percent to $171.9 million, or 42 percent of total CVI revenue. Sales to Asia Pacific rose by 9 percent for the quarter while sales in EMEA rose two percent for the period.

In April 2017, the company repurchased $29.5 million of common stock under the existing share repurchase program for an average share price of $196.82. The program was expanded by $500.0 million on March 21, 2017, has $589.0 million of remaining availability and no expiration date.